A serum metabolite panel predicts Crohn’s disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial.
“A serum metabolite panel predicts Crohn’s disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial”, Radford-Smith D.E., Satsangi J., Louis E., Laharie D., Ding Siegmund B., D’Haens G., Hertervig E., Yates A., Anthony D.C., Colombel J.F., Probert F., GETAID and the SPARE-Biocycle research group., Journal of Crohn’s and Colitis,…